Advertisement
Organisation › Details
US Patent and Trademark Office (USPTO)
Start | 1998-05-27 existent | |
Group | United States (govt) | |
Industry | IP services | |
City | n. a. | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Record changed: 2023-11-10 |
Advertisement
More documents for United States (govt)
- [1] Roche. (4/11/24). "Press Release: Roche Granted FDA Breakthrough Device Designation for Blood Test to Support Earlier Alzheimer's Disease Diagnosis". Basel....
- [2] Basilea Pharmaceutica Ltd.. (4/4/24). "Press Release: Basilea Announces US FDA Approval of Antibiotic Zevtara (ceftobiprole medocaril) for Three Indications". Allschwil....
- [3] Idorsia Ltd.. (3/20/24). "Press Release: US FDA Approves Idorsia’s Once-daily Tryvio (aprocitentan) – the First and Only Endothelin Receptor Antagonist for the Treatment of High Blood Pressure Not Adequately Controlled in Combination with other Antihy...
- [4] Omnix Medical Ltd.. (2/20/24). "Press Release: Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6". Jerusalem....
- [5] Valneva S.E.. (11/10/23). "Press Release: Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, Ixchiq". Saint Herblain....
- [6] Immunic, Inc.. (11/2/23). "Press Release: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts". New York, NY....
- [7] Santhera Pharmaceuticals Holding AG. (10/27/23). "Press Release: Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy [Ad hoc announcement pursuant to Art. 53 LR]". Pratteln....
- [8] MetrioPharm AG. (10/25/23). "Press Release: MetrioPharm Receives Rare Pediatric Disease Designation (RPDD) for MP1032 from the U.S. FDA". Zurich....
- [9] Immatics N.V.. (10/24/23). "Press Release: Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy". Houston, TX & Tübingen....
- [10] Agomab Therapeutics N.V.. (10/5/23). "Press Release: Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial". Ghent....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top